One of the biggest meetings of the world’s cancer specialists took place this weekend. Usually located in Chicago, researchers and clinicians around the world met virtually this year to present the latest in cancer research at the American Society of Clinical Oncology (ASCO) annual meeting. Here’s a flavour of the some of the top research presented.
Hormone treatment enzalutamide will now be offered as an alternative combined treatment option for some adults with prostate cancer on the NHS in England.
Our partnership with ScottishPower began in 2012, since then it’s raised over £30m. We’re thrilled to announce that we’re extending this extraordinary partnership for another three years.
The director of our Cancer Research UK Edinburgh Centre walks us through some of his proudest research achievements and how supporters have made them possible.
Teasing apart causation from correlation is vital if we are to understand whether the gut microbiome changes the risk of cancer or whether cancer changes the gut microbiome
Widely-used anti-inflammatory drugs make tumours in mice more responsive to treatments that harness the power of the body’s own immune system to tackle cancer, according to research funded by Cancer Research UK and published in the journal Cancer Discovery.
Cancer Research UK estimates that 3 million fewer people were screened for cancer between March and September last year, meaning around 9,200 fewer patients started cancer treatment as a result in England alone – a 42% drop.
We explore how our partner, Credit Suisse, adapted to significant changes in the fundraising environment to exceed its original targets for the partnership.
After a very difficult year for cancer clinical trials, we look to the future and ask what positive lessons can be learnt